Nicotine E-Cigarettes are More Effective in Smoking Cessation

Industry Insight by 2FIRSTS.ai
Jan.09.2024
Nicotine E-Cigarettes are More Effective in Smoking Cessation
A new review by a public health researcher at UMass Amherst suggests that nicotine e-cigarettes are more effective for quitting smoking than traditional nicotine replacement therapy.

According to a report by metronews on January 9, a recent review conducted by a public health and health policy researcher at the University of Massachusetts Amherst suggests that nicotine e-cigarettes are more effective in helping people quit smoking compared to traditional nicotine replacement therapy.

 

A review conducted on studies published in the Cochrane Database of Systematic Reviews found that e-cigarettes, which allow users to inhale nicotine without smoking, are more effective in helping smokers quit compared to patches, gums, lozenges, or other traditional nicotine replacement therapies. The review also found strong evidence to support this view. While acknowledging that nicotine e-cigarettes are not without risks, the study concluded that they are significantly less harmful to health. Research in countries such as the United States, the United Kingdom, and Italy has shown that e-cigarettes containing nicotine pose a lower risk compared to traditional cigarettes.

 

A study has shown that out of every 100 people who use nicotine e-cigarettes to quit smoking, it is expected that 8-10 individuals will successfully quit. In comparison, among those who use traditional nicotine replacement therapies, 6 people are able to successfully quit, and out of those who attempt to quit without any assistance, 4 people are successful.

 

Despite controversy, the research authors emphasize the positive role of nicotine e-cigarettes in aiding smoking cessation. It is important to note that the study specifically highlights the potential negative impact of using e-cigarettes for non-smokers when discussing the possibility of improving health through nicotine e-cigarettes.

 

Despite the approval of various medications by the Food and Drug Administration (FDA) to aid adults in quitting smoking, nicotine e-cigarettes have yet to be included. FDA Commissioner Robert Califf stated in an update on the tobacco program earlier this year, "While some nicotine e-cigarettes may assist adult smokers in completely quitting or significantly reducing their use of more harmful combustible cigarettes, public health regulations must balance this potential with the known, considerably high risks of these products' appeal, adoption, and addictiveness among young people.

 

This study provides strong evidence for public health policies and smoking cessation strategies, offering better tools for smokers to quit. While the effects of e-cigarettes on health are complex, quitting smoking through the use of e-cigarettes may be a pathway towards improving health for smokers.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Jiangsu Industrial Patent Points to 3D-Printed Nicotine Oral Products
China Tobacco Jiangsu Industrial Patent Points to 3D-Printed Nicotine Oral Products
Jiangsu China Tobacco Industrial Co., Ltd. has disclosed a patent describing a nicotine oral formulation produced using 3D printing technology. The invention enables a three-stage nicotine release system—rapid onset, sustained delivery and long-term release—through a layered structure with varying porosity. The technology reflects growing experimentation within China Tobacco’s research system around precision nicotine delivery for modern oral products.
Mar.09
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
Product | Full-screen display and 10K puffs: IVG launches new Pro-series pod vape in the UK
Product | Full-screen display and 10K puffs: IVG launches new Pro-series pod vape in the UK
E-cigarette brand IVG has recently rolled out the IVG Pro 2 across several UK online retailers. The device is compatible with IVG Pro pods and comes in 33 flavours with nicotine strengths of 0mg, 10mg and 20mg. Channel listings show a 2ml prefilled pod paired with a 10ml refill container, with pricing around £9.99.
Feb.02 by 2FIRSTS.ai
PMI reshuffles U.S. footprint: Swedish Match to shut Richmond office in April; most staff may be relocated
PMI reshuffles U.S. footprint: Swedish Match to shut Richmond office in April; most staff may be relocated
Swedish Match, a unit of Philip Morris International (PMI), will close its office in Richmond, Virginia, in April 2026 and eliminate 135 positions. PMI said the move is tied to adjustments in its U.S. operating footprint.
Feb.03
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE® Nicotine Pouches announced a partnership with Taylor Reimer Racing, becoming the Official Nicotine Sponsor for four races in the 2026 ARCA Menards Series and serving as the primary sponsor at events in Alabama, Michigan, Minnesota, and Arizona. FRE branding will appear on the race car, driver suit, and helmet, and the collaboration will also extend to off-track content and activations.
Feb.27
BAT Japan Announces McLaren Collaboration “glo Hilo Plus” Limited-Edition Set, Priced at About USD 200
BAT Japan Announces McLaren Collaboration “glo Hilo Plus” Limited-Edition Set, Priced at About USD 200
British American Tobacco Japan (BAT Japan) announced a collaboration with McLaren Racing to launch the “glo Hilo Plus・McLaren Racing Inspired Limited-Edition Set.” Sales begin on March 3 via the glo Store Ginza and the official glo online store. Based on the “glo Hilo Plus,” the set includes a limited-edition device and dedicated accessories, priced at JPY 30,000 (about USD 200).
Mar.03 by 2FIRSTS.ai